



ASX ANNOUNCEMENT

7 November 2014

Restricted Securities to be released from ASX Escrow

In accordance with ASX Listing Rule 3.10A, the Board of Cynata Therapeutics Ltd (ASX: CYP) hereby advises that 10,000,001 ordinary fully paid shares will be released from escrow with effect from close of business on 21 November 2014.

The relevant shares are held by founder investors of the Company and include such shareholders as Professor Igor Slukvin and Dr Maxim Vodyanik (the inventors of Cynata's Cymerus™ technology) who remain closely involved in an advisory capacity, and Dr Ian Dixon, the Chair of Cynata's Scientific Advisory Board.

Media contacts: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.